期刊文献+

甲状腺功能减退症并抗利尿激素分泌异常综合征1例分析

原文传递
导出
出处 《中国误诊学杂志》 CAS 2009年第3期730-731,共2页 Chinese Journal of Misdiagnostics
  • 相关文献

参考文献1

二级参考文献33

  • 1Soupart A, Penninckx R, Crenier L, et al. Prevention of brain demyelination in rats after excessive correction of chronic hyponatremia by serum sodium lowering. Kidney Int, 1994,45: 193-200. 被引量:1
  • 2Sterns RH, Silver SM. Hemodialysis in hyponatremia: is there a rish? Semin Dial, 1990;3:3 被引量:1
  • 3Oh MS, Kim HJ, Carroll HJ. Recommendations for treatment of symptomatic hyponatremia. Nephron, 1995, 70: 143-150. 被引量:1
  • 4Soupart A, Ngassa M, Decaux G. Therapeutic relowering of serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol, 1999,51:383-386. 被引量:1
  • 5Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am, 1997,81:585-609. 被引量:1
  • 6Yamamura Y, Ogawa H, Yamashitat H, et al. Characterization of a novel aquaretic agent, OPC 31260, as an orally effective,nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol,1992, 105: 787-791. 被引量:1
  • 7Serradeil-Le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res,2002, 139: 197-210. 被引量:1
  • 8Abraham WT, Oren RM, Schrier RW. Effects of an oral nonpeptide, selective V2 receptor vasopressin antagonist in human heart failure (Abstract). In: World Congress of Neurohypophysial Hormones, Montreal, Canada, August 8-12, 1997. 被引量:1
  • 9Udelson JE, Smith WB, Henrix GH et al. Hemodynamic effects of conivaptan hydrochloride (YM 087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist in patients with advanced heart failure. Circ, Suppl 2000,102(18): Ⅱ-593. 被引量:1
  • 10Kuhn K, Reimann D, Gross P. Beneficial effects (antag) in the hyponatremia of clinical cardiac failure (CHF), SIADH and cirrhosis (C1) (abstract). Kidney Blood Pressure Res, 1998,21:183. 被引量:1

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部